Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
11 stopped studies mapped to Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase and descendants · 73% state a reason
Over the 11 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT04551066 | To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With… | Phase 3 | terminated | Sep 16, 2020 | Incyte Corporation | The study was terminated due to futility. | Efficacy / futility |
| NCT04551053 | To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With… | Phase 3 | terminated | Sep 16, 2020 | Incyte Corporation | The study was terminated due to futility. | Efficacy / futility |
| NCT03755518 | A Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary…(FREEDOM) | Phase 3 | terminated | Nov 28, 2018 | Celgene | Slow accrual. | Enrollment / accrual |
| NCT04896112 | A Study of LNK01002 in Patients With Primary or Secondary Myelofibrosis,Polycythemia Vera… | Phase 1 | withdrawn | May 21, 2021 | Lynk Pharmaceuticals Co., Ltd | sponsor decision | Sponsor / business decision |
| NCT02055781 | Pacritinib Versus Best Available Therapy to Treat Patients With Myelofibrosis and…(PAC326) | Phase 3 | terminated | Feb 5, 2014 | CTI BioPharma | not stated | Not stated |
| NCT04283526 | Study of Select Combinations in Adults With Myelofibrosis | Phase 1 | withdrawn | Feb 25, 2020 | Novartis Pharmaceuticals | This study was cancelled before enrolling any patients for business related reasons. | Enrollment / accrual |
| NCT01773187 | Pacritinib Versus Best Available Therapy to Treat Myelofibrosis | Phase 3 | terminated | Jan 23, 2013 | CTI BioPharma | not stated | Not stated |
| NCT02871323 | Durvalumab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential… | Phase 1 | withdrawn | Aug 18, 2016 | Northwestern University | PI decided to withdraw the study after it opened for enrollment but before any patients were… | Enrollment / accrual |
| NCT04054245 | PAT-1251 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera… | Phase 2 | withdrawn | Aug 13, 2019 | M.D. Anderson Cancer Center | "Company is in a process of being taken over by another pharma and the new one has different ideas… | Sponsor / business decision |
| NCT02421354 | Nivolumab in Treating Patients With Primary Myelofibrosis, Post-Essential Thrombocythemia… | Phase 2 | terminated | Apr 20, 2015 | M.D. Anderson Cancer Center | not stated | Not stated |
| NCT01291784 | Anti-TGF-beta Therapy in Patients With Myelofibrosis | Phase 1 | terminated | Feb 8, 2011 | John Mascarenhas | Early termination when the drug was no longer made available by the pharmaceutical company due to… | Sponsor / business decision |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated Oct 21, 2025source: clinicaltrials